Galera Therapeutics, Inc. Annual Report - How They Did This Year

Here's a look at Galera Therapeutics, Inc. and how they've been doing. We'll explain it simply so you understand the company better.

1. What does this company do and how did they perform this year?

Galera Therapeutics once developed drugs to lessen cancer radiation side effects. But late 2024 and 2025 brought huge changes for the company.

• Big Strategic Shift: In October 2025, Galera sold its old drug assets, like avasopasem and rucosopasem, to Biossil, Inc. They got $3.5 million upfront. They could receive up to $105 million more if future development, regulatory, and sales goals are met. This sale completely changed their drug development focus.
• New Direction: Before this, in December 2024, they bought Nova Pharmaceuticals, Inc. This purchase completely shifted their strategy and gave them a new main drug.
• Current Focus: Now, Galera develops a new drug, a "pan-NOS inhibitor." It treats aggressive breast cancers like metaplastic (MpBC) and hard-to-treat triple-negative (TNBC). This drug stops nitric oxide synthases. These enzymes can help tumors grow and resist treatment.
• Current Status: Their main drug is now in a Phase 1/2 clinical trial for MpBC. The National Institutes of Health (NIH) funds this trial. Houston Methodist researchers run it. This greatly cuts Galera's direct development costs. In 2025, they reached Phase 2a and expanded the trial to two more cancer centers. This shows good progress. They also plan a second trial for TNBC. But they need more funding first.
• Team Size: Galera is a very small company. As of December 31, 2025, it had only 3 employees. This lean structure fits their stage as a single-drug company. They rely heavily on outside help for trials and manufacturing.

Overall, 2025 was not about typical financial results. It was about completely reinventing the company. They shifted to a new drug development area. They have no products for sale yet. So, they earn no money from sales.

2. Financial performance - revenue, profit, growth metrics

Galera has never earned money from selling products. They have lost a lot of money since they started. They expect these losses to continue. Developing their new drug is costly and takes a long time.

This year, they received crucial cash from strategic moves. These are one-time payments:

• They got $3.5 million upfront in October 2025. This was from selling old drug assets like avasopasem to Biossil, Inc.
• They also secured a $2.9 million investment in December 2024. Ikarian Capital led the investors. This helped fund the Nova Pharmaceuticals purchase.

These are positive cash injections. But they aren't from product sales. They don't mean the company is becoming profitable or earning steady money. The company still loses a lot of money. This is normal for a drug company developing new medicines.

3. Major wins and challenges this year

Big Wins:

• Strategic Pivot: They successfully made a bold strategic shift. They sold their old drug pipeline in October 2025. Then, they bought Nova Pharmaceuticals in December 2024. This move redefined their future. It gave them a new main drug for advanced breast cancer.
• New Drug Progress: Their new main drug for breast cancer, the pan-NOS inhibitor, is already in a Phase 1/2 trial. A big advantage is that the NIH funds this trial. Researchers run it. This greatly cuts Galera's direct research costs. They expanded the Phase 2a trial to more sites in 2025. This shows good momentum.
• Funding for Acquisition: They secured $2.9 million from Ikarian Capital. This helped fund the Nova purchase. It shows investors trust their new direction.
• Potential Future Payments: Selling old assets to Biossil could bring up to $105 million more. This depends on reaching development, regulatory, and sales goals. It's a potential future funding source that won't issue more shares.

Challenges:

• Stopped Development: They stopped developing most old drugs, like avasopasem. Years of investing tens of millions didn't lead to a product for Galera. This means a lot of money was spent with no return.
• No Sales: They have no products on the market. So, no sales money covers their operating costs.
• Big Losses: They keep losing a lot of money. These losses will likely continue as they fund drug trials.
• Risk of Not Surviving: This is a big worry for investors. Galera states they need more funding to keep operating. This is in their financial reports. Their current cash will only last until early 2027. If they don't raise money, the company's future is at risk.
• OTCQB Stock Listing: Their stock now trades on the OTCQB Market. This exchange is less known and regulated than Nasdaq or NYSE. This can mean less trading, making it harder to buy or sell shares. There's also less analyst coverage. This could hurt the stock price and their ability to raise money.
• Tiny Team: With only 3 employees as of December 31, 2025, they have few internal resources. They rely heavily on outside contractors and partners. This can create operational risks.

4. Financial health - cash, debt, liquidity

Galera's financial health is very tight. This is a major risk. As of December 31, 2025, their cash will only fund operations until early 2027.

They urgently need to raise a lot more money. This will keep the company running and fund their drug trials. This is a serious investor concern, a "risk of not surviving." If they don't get more funding, the company could stop operating. It might sell assets or go bankrupt. This would greatly hurt shareholder value. They got some cash this year: $3.5 million from selling assets and a $2.9 million investment. But these funds aren't enough for long-term operations. The company has no major debt. But this also limits their options for funding that doesn't issue more shares.

5. Key risks that could hurt the stock price

• Running Out of Cash (Risk of Not Surviving): This is likely the biggest and most immediate risk. Galera needs a lot more funding to operate past early 2027. If they can't raise this money, the company's future is uncertain. The stock price would likely fall sharply, possibly becoming worthless.
• All Hopes on One Drug: Their entire future depends on one new drug: the pan-NOS inhibitor for breast cancer. If this drug fails trials, isn't approved, or doesn't sell well, the company could face serious financial trouble or failure.
• Long, Risky Drug Approval: Getting a new drug approved by regulators, like the FDA, is very hard. It's expensive and long, often taking 10-15 years. Costs can be hundreds of millions to billions of dollars. There's no guarantee their drug will reach the market. Many drugs fail during development.
• No Sales Money: They have no products making sales now. They expect big losses to continue. This means they'll always need outside funding.
• OTCQB Stock Listing: Trading on the OTCQB Market means less visibility. It can lead to lower trading volume and harder-to-sell shares. This might result in a lower stock price than on a major exchange. It also makes it harder to attract big investors and raise money.
• Relying on Others: Galera has a small team. It relies heavily on others to run trials, like NIH/Houston Methodist. They also depend on others to make their drug. If partners perform poorly, face delays, or if Galera loses control, it could greatly delay their plans.
• Competition: The drug industry is very competitive. Other companies might develop better, safer, or faster breast cancer treatments. Existing therapies could also improve. This would reduce Galera's potential market share.
• Drug Side Effects: Even if the drug works, unexpected severe side effects could appear. This could happen in later trials or after approval. It might prevent approval or limit sales, hurting its market potential and stock price.
• Market Size & Payment: Fewer patients might benefit from their drug than estimated. Even if approved, getting good prices and payment from insurers is a huge challenge. This can greatly affect how much money they make.
• Uncertain Future Payments: The potential $105 million from Biossil isn't guaranteed. It depends on future development, regulatory, and sales goals. These may or may not be met. So, it's an unreliable future funding source.

6. Competitive positioning

Galera works in a very competitive drug industry. Their new focus is a pan-NOS inhibitor. It targets specific, aggressive breast cancers. These include metaplastic and refractory triple-negative types. This strategy targets areas with high unmet medical needs. This could be an advantage if their drug works for these tough patient groups. Targeting unmet needs can sometimes speed up approval. It might also allow for higher prices.

7. Leadership or strategy changes

This year, Galera completely changed its strategy and operations. This was a fundamental company transformation.

• Big Strategic Change: They completely changed their drug focus. They moved from radiation side effects to a new drug for advanced breast cancer. This was a planned decision. They chose a new path after past trial failures.
• Selling Assets & Buying a Company: They sold their old drug pipeline, like avasopasem, to Biossil in October 2025. At the same time, they bought Nova Pharmaceuticals in December 2024. This was specifically to get their new main drug, the pan-NOS inhibitor.
• Lean Operations: The company now operates with a very lean team. As of December 31, 2025, it had just 3 employees. This big restructuring and smaller workforce shows a focused approach. They aim to save money and direct resources. These go almost entirely to developing their new main drug. They rely heavily on outside partners to get things done.

8. Future outlook

Galera's future depends entirely on its new drug. The pan-NOS inhibitor for advanced breast cancer must succeed in development. It must also get regulatory approval. This is a high-risk, high-reward situation.

They plan to advance their main program through its Phase 1/2 trial. They hope to expand it and start a second trial for triple-negative breast cancer. Good trial data will be key to attracting more investment and moving the program forward. But a critical part of their future is getting more funding. They need it to operate past early 2027. They also need it to finance their ambitious drug development plans. Without more money, their future is very uncertain. The company might not be able to continue operating. They also hope for more payments from selling old assets to Biossil. This could provide more funding without issuing new shares. But these payments depend on conditions and aren't guaranteed.

9. Market trends or regulatory changes affecting them

The drug industry has long development times, often 10-15 years. Costs are high, over $1 billion per approved drug. There are also big regulatory hurdles. Galera's success depends on handling these challenges well. They focus on advanced breast cancer, especially metaplastic and refractory triple-negative types. This targets areas with high unmet medical needs. This can sometimes bring benefits like faster approval paths. Examples include Fast Track or Breakthrough Therapy status. It might also lead to orphan drug status or higher prices after approval. Drug development competition is growing. They will need a truly unique product. It must have strong trial data to succeed. The need for more funding also shows a wider market trend. Small biotech companies often rely on outside money. This includes venture funding or partnerships. This is especially true given the high spending rates for drug trials.

So, what does all this mean for you as an investor? Galera Therapeutics is a company undergoing a massive transformation, betting its future on a single, promising drug for aggressive cancers. This is a high-risk, high-reward situation. On one hand, success could mean big returns, especially with the NIH funding and potential milestone payments. On the other hand, the company faces significant financial challenges, relies heavily on external funding, and has all its eggs in one basket. Your decision will depend on your comfort with these risks and your belief in their new drug's potential.